Before 1998, urokinase was considered standard therapy for the management of occluded hemodialysis catheters. The dose of 5000 units per port appears on the FDA-approved labeling for urokinase.

Central venous catheter-related blood stream infection (CRBSI) is a major cause of morbidity and mortality in patients with end-stage renal disease treated with chronic hemodialysis. Risk factors ...

In 2023, the catheter market is projected to surge to a size of around USD 12,591.30 million. In the forecast period from ...

While medical device shortages are nothing new, the FDA said it is becoming more concerned that supply chain disruptions are ...

The success of PD largely depends on the proper placement and management of the dialysis catheter. Recent research has focused on various techniques for catheter insertion, the impact of intra ...

The study, published in Kidney360, found that patients on home hemodialysis had a 42% lower risk of stroke, 17% lower risk of acute coronary syndrome, 22% lower risk of cardiovascular death and 8% ...

This medication is given by injection into the dialysis catheter, as directed by your doctor, usually at the end of each dialysis treatment. Do not inject this medication into the body.

The effectiveness of alteplase and urokinase in restoring adequate hemodialysis blood-flow rates was examined. A retrospective review of the medical records of hemodialysis patients with central ...